fluorouracil has been researched along with sildenafil citrate in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Davis, WM; Waters, IW | 1 |
Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C | 1 |
Booth, L; Dent, P; Hancock, JF; Poklepovic, A; Roberts, JL | 1 |
1 trial(s) available for fluorouracil and sildenafil citrate
Article | Year |
---|---|
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
3 other study(ies) available for fluorouracil and sildenafil citrate
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A new-drug roundup.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Capecitabine; Cyclopropanes; Deoxycytidine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Etanercept; Fluorouracil; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Phosphodiesterase Inhibitors; Piperazines; Purines; Quinolines; Receptors, Tumor Necrosis Factor; Rifampin; Sildenafil Citrate; Sulfides; Sulfones; Thionucleotides | 1999 |
(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Curcumin; Drug Synergism; Fluorouracil; Histone Deacetylases; Humans; Mice; Mice, Inbred BALB C; Programmed Cell Death 1 Receptor; Sildenafil Citrate; Vasodilator Agents; Xenograft Model Antitumor Assays | 2020 |